DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...

Fifth Third Bancorp grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm ...

today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better ...

In June, DexCom announced the integration of its G6 CGM system with Insulet’s Omnipod 5 Automated Insulin Delivery System for Type 1 diabetes patients. The same month, the company announced the ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...

Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains ...

Strong Product Demand: We are upbeat about DexCom's continued strength in CGM products. DexCom demonstrated strong product demand in third-quarter 2024, highlighted by record new patient starts in ...